EMA Refused: Xeljanz (tofacitinib) — Pfizer Limited

View source ↗

Summary

The EMA refused approval for Xeljanz (tofacitinib) by Pfizer Limited in the rheumatoid arthritis therapeutic area.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• XELJANZ (tofacitinib)

Snippet

Status: Refused. Therapeutic area: Arthritis, Rheumatoid. MAH: Pfizer Limited. Decision date: 23/07/2018